Viral evolution and COVID-19 vaccines

Jesse Bloom

Fred Hutch Cancer Center / HHMI

These slides at https://slides.com/jbloom/awaji-cov-vax

Broad evolutionary patterns in human coronavirus evolution relevant to vaccines

CoV-229E causes common colds and has been circulating in humans for a long time.

How do other human coronaviruses evolve?

Evolution of CoV-229E spike

We experimentally generated CoV-229E spikes at ~8 year intervals to study in the lab:

- 1984

- 1992

- 2001

- 2008

- 2016

Eguia et al (2021)

Evolution of CoV-229E spike erodes neutralization by human serum antibodies

Eguia et al (2021)

Ideally vaccines would elicit evolution-resistant antibodies (like those made by person at right) rather than evolution-sensitive antibodies (like those made by person at left)

Evolution erodes neutralization by sera from different people at different rates

Eguia et al (2021)

We now know SARS-CoV-2 evolves to erode neutralizing antibodies, just like CoV-229E

Original vaccine induced high neutralizing antibody titers against early viral strains

Lasrado et al (2023)

In SARS-CoV-2 evolution, new variants replace old ones (just like for CoV-229E)

Sites of evolutionary change in the spike of CoV-229E over the last four decades

Sites of mutations in the current KP.3.1.1 SARS-CoV-2 variant relative to the early Wuhan-Hu-1 strain

CoV-229E and SARS-CoV-2 acquire mutations in analogous regions of spike

The most intense evolutionary selection is in the receptor-binding domain (RBD)

Phylogenetic tree shape & vaccine strategy

CoV-229E has ladder-like tree:

• new variants displace old ones
• new variants descend from recent successful ones

Human influenza A evolves this way too. It's theoretically possible to pick single well-matched vaccine strain.

Phylogenetic tree shape & vaccine strategy

CoV-OC43 split into two ladder-like lineages. Influenza B evolved this way too (until very recently). It's theoretically possible to pick well-matched bivalent vaccine.

Phylogenetic tree shape & vaccine strategy

Mutational drivers of SARS-CoV-2 antigenic evolution

Types of mutations relevant to SARS-CoV-2 antigenic evolution:

1. Direct antibody-escape mutations in the RBD
2. Direct antibody-escape mutations in the NTD
3. Mutations that modulate RBD "up" versus "down" conformation

Types of mutations relevant to SARS-CoV-2 antigenic evolution:

1. Direct antibody-escape mutations in the RBD
2. Direct antibody-escape mutations in the NTD
3. Mutations that modulate RBD "up" versus "down" conformation

The RBD is antigenically very important

Greaney et al (2021)

As shown on an earlier slide, the RBD is the most intense region of evolutionary selection in both SARS-CoV-2 and CoV-229E.

RBD-binding antibodies are responsible for most neutralizing activity in sera from humans vaccinated or infected with the original viral strain (see plot at right).

BA.2 had mutations at key sites of RBD escape in original RBD (eg, sites 484, 417)

XBB had mutations at key sites of RBD escape in BA.2 (eg, sites 346, 444, 445, 486)

RBD sites that currently most escape binding by neutralizing antibodies

Mutations at epitope with sites 403, 405, 504, 505 currently escape binding by RBD antibodies, but mutations at these sites have pleiotropic effects on RBD up-down (see here)

Types of mutations relevant to SARS-CoV-2 antigenic evolution:

1. Direct antibody-escape mutations in the RBD
2. Direct antibody-escape mutations in the NTD
3. Mutations that modulate RBD "up" versus "down" conformation

Although most neutralizing activity targets RBD, NTD antibodies also important

As described earlier in this talk, NTD is also a hotspot of mutations in both SARS-CoV-2 and CoV-229E. Many SARS-CoV-2 NTD mutations are in antigenic supersite.

As described in my Sunday talk at this meeting, NTD antibodies can be major contributors to neutralization in young individuals infected by recent variants

Types of mutations relevant to SARS-CoV-2 antigenic evolution:

1. Direct antibody-escape mutations in the RBD
2. Direct antibody-escape mutations in the NTD
3. Mutations that modulate RBD "up" versus "down" conformation

Image from Liu and Wilson (2022)

all-down RBDs

1-up RBD

2-up RBDs

3-up RBDs

RBD must go into up conformation to bind ACE2, but that increases antibody exposure

Most potent neutralizing epitopes are shown in red, and are more exposed in up RBD

Mutations that put RBD in down position reduce neutralization by polyclonal sera antibodies

Later SARS-CoV-2 variants have more down RBD than early variants (Zhang et al, 2024)

Mutations that put RBD more down have contributed to evolution of variants (Dadonaite et al, 2024), including NTD mutations that promote down RBD in recent KP.3.1.1 and XEC variants (Wang et al, 2024)

"Common-cold" coronaviruses that are highly adapted to humans have RBD mostly in down conformation (Pronker et al, 2023)

Summary

Human coronaviruses, including SARS-CoV-2, evolve to erode antibody neutralization.

Standing genetic diversity is low even though viral spike changes rapidly over time. This fact forms the basis for the strategy of regular vaccine strain updates.

Antigenic evolution is mostly due to mutations in the RBD and to a lesser extent NTD.

Initially SARS-CoV-2 antigenic evolution primarily involved mutations in RBD that escaped antibody binding. This remains important, but recently there has been increased role of mutations in NTD, including ones that shift RBD to more down position.

As exposure histories and imprinting become more diverse, the antibody pressure on SARS-CoV-2 imposed by the human population will become more heterogeneous.

Bloom lab

These slides: https://slides.com/jbloom/awaji-cov-vax

Thanks

Fred Hutch Cancer Center

Trevor Bedford

University of Washington

Helen Chu and HAARVI cohort

Neil King

David Veesler

Cincinnati Children's Hospital

Mary Staat

David Haslam

Allie Burrell

Kate Crawford

William Hannon

Caelan Radford

Brendan Larsen